Cerini

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cerini

What is Cerini? (Overview)

Property Description
Active ingredient Cetirizine Hydrochloride
Form Tablet, Oral Solution, Syrup (Oral)
Pharmacological class H1 Receptor Antagonist
Common use Relief of allergic symptoms
Origin Synthetic, second-generation compound

What Type of Medicine is Cerini? (Classification and Identity)

Cerini is a medication whose active ingredient, Cetirizine Hydrochloride, is classified as a second-generation Antihistamine and a selective H1 Receptor Antagonist. This means the drug is a synthetic compound designed to provide systemic relief by blocking the effects of histamine, the natural chemical messenger responsible for triggering allergic responses, a function clinically recognized across international pharmacopoeias. The distinction as a second-generation agent indicates its chemical structure, supported by pharmacological studies, minimizes central nervous system penetration compared to older antihistamines. This characteristic ensures the medication remains effective at the peripheral target sites while generally exhibiting a lower potential for causing drowsiness, which has made it a preferred choice for daytime use.


Core Composition: Cetirizine Hydrochloride and Available Forms

The therapeutic action of Cerini is delivered solely by its active component, Cetirizine Hydrochloride, establishing it as a single-ingredient product. This substance is a dihydrochloride salt engineered for targeted action. Cerini is typically available in a variety of common oral administration forms for systemic effect, including the standard compressed tablet, as well as liquid preparations such as an oral solution and syrup. The availability of a specific oral solution, often formulated to be palatable, allows for flexible dosing, especially accommodating pediatric patients or adults who may have difficulty swallowing tablets.


General Purpose of Cerini in Allergic Conditions

The primary general purpose of Cerini is to provide relief of symptoms associated with allergic responses and hypersensitivity reactions. For instance, it is commonly used to manage the uncomfortable physical manifestations of seasonal allergies. The medication functions as a selective Histamine receptor blocker, competitively binding to peripheral H1 receptors to prevent histamine from activating them. By interrupting this chemical cascade, the medication effectively helps to mitigate the unwanted physical manifestations of allergic conditions.

Regulatory References

  1. FDA Cetirizine Hydrochloride Oral Solution Label

What side effects are possible with Cerini?

The safety profile of Cerini (Cetirizine Hydrochloride) is officially documented by regulatory authorities, with adverse reactions classified by frequency and body system affected.

Frequency-Classified Adverse Reactions

Adverse effects are categorized based on their rate of occurrence reported in clinical use:

Classification Examples of Officially Documented Reactions
Common (ge 1/100) Somnolence (drowsiness), headache, fatigue, dry mouth, nausea, pharyngitis, dizziness.
Uncommon (ge 1/1,000) Paresthesia, diarrhea, pruritus (itching), rash, asthenia (weakness).
Rare (ge 1/10,000) Tachycardia, edema, weight increase, aggression, confusion, insomnia, hepatitis.
Very Rare (< 1/10,000) Anaphylactic shock, angioedema, tremor, dyskinesia, syncope, thrombocytopenia.

Serious Adverse Reactions and Safety Considerations

Reactions classified as Rare or Very Rare include severe hypersensitivity reactions, such as anaphylactic shock and angioedema, along with less frequent events affecting the liver, such as hepatitis. The inclusion of these effects in regulatory labeling defines the most serious, though highly infrequent, risks associated with the medicine.

Official documents define certain constraints for use. The medication is contraindicated in individuals with severe renal impairment (creatinine clearance less than 10 mL/min). Furthermore, labeling notes that older adults may experience a higher likelihood of adverse reactions. Time-related safety patterns indicate that certain effects, like somnolence and headache, may be more pronounced at the beginning of treatment. Safety notes also advise of the potential for additive effects if taken concurrently with alcohol or other central nervous system depressants.

Overdose and Emergency Response

The official regulatory profile for Cerini (Cetirizine Hydrochloride) details the documented manifestations of overdose, which are primarily associated with the central nervous system. Overdose presentations can include a spectrum of effects, such as profound somnolence, sedation, fatigue, and malaise, or, conversely, states of restlessness and tremor. Additional reported physiological signs include tachycardia (rapid heart rate), diarrhea, mydriasis (pupil dilation), and urinary retention. Severe outcomes, such as a significantly decreased level of consciousness or the potential for cardiac arrhythmia following large ingestions, warrant clinical evaluation.

Official regulatory guidance strictly mandates that in case of overdose, one must get medical help or contact a Poison Control Center right away. Urgent professional assistance is required immediately upon accidental overdose, and emergency services must be called if a person has collapsed, had a seizure, or cannot be awakened. The regulatory documents state there is no known specific antidote for Cerini overdose, and the substance is not effectively removed by dialysis. Therefore, clinical management is restricted to symptomatic and supportive treatment, with monitoring, including cardiac monitoring for large overdoses, being a necessary component of care.

Therapeutic Uses of Cerini

What Cerini Treats: Main Uses and Benefits

Cerini is commonly used for managing symptoms related to heightened physiological activity, primarily across conditions involving episodic or fluctuating manifestations, including allergic rhinitis (hay fever) and chronic idiopathic urticaria (hives). It is commonly applied in scenarios where additional management of discomfort is required for conditions like hay fever, runny or itchy nose, itchy, watery eyes, and skin rashes or itching.

It is applied in addressing symptom clusters that may become intense or disruptive, relevant for managing symptoms that interfere with daily comfort, particularly those affecting the respiratory system, eyes, and skin.

“This medication is relevant for easing symptoms related to inflammatory or irritative states, contributing to improved comfort during periods of heightened symptoms.”

This medication is commonly used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with daily functioning. It contributes to maintaining a sense of stability when symptoms are more noticeable, and supports general well-being during symptomatic phases.


Quick Fact: Relief for Itching and Nasal Symptoms

Eligibility and Restrictions for Use

Who Can and Cannot Use Cerini

Official regulatory information strictly defines the eligible populations and absolute restrictions for Cerini (Cetirizine Hydrochloride).


Eligibility Scope and Restrictions

Classification Eligibility Rule (Official Regulatory Status)
Absolute Contraindication Patients with a known hypersensitivity to Cetirizine Hydrochloride, Hydroxyzine, or any piperazine derivatives.
Individuals with severe renal impairment (e.g., Creatinine Clearance le 10 ml/min).
Age Restriction Infants under 6 months of age must not use the medicine, as safety and efficacy are not established.
Adults and adolescents 12 years and older are generally eligible for standard use.
Conditional Use Use is not recommended for women who are breastfeeding, as the drug is excreted in breast milk.
Use during pregnancy is generally restricted and advised only if clearly necessary.
Caution is advised for patients with moderate renal impairment or those with a predisposition to urinary retention; use is conditional on dosage assessment.

Summary of Eligibility Structure

The regulatory profile classifies the use of Cerini into allowed, restricted, or prohibited categories based on patient characteristics. Eligibility is defined by ruling out absolute contraindications (hypersensitivity and severe kidney disease) and by applying restrictions based on age and key physiological states, ensuring use is limited to populations where safety and appropriate drug clearance are officially documented.

What should I know about interactions with other medicines?

Cerini's interaction profile, as documented in government regulatory information, details specific pharmacokinetic (PK) and pharmacodynamic (PD) interactions with other substances. The most consistent pharmacodynamic interaction occurs with alcohol and other Central Nervous System (CNS) depressants. Co-administration with these substances is officially documented to have an additive effect, which may result in an additional reduction in alertness and further impairment of CNS performance. Due to this official finding, co-administration with alcohol or other CNS depressants carries a caution regarding enhanced sedation.

A documented pharmacokinetic interaction exists with Theophylline. Regulatory studies show that co-administering a 400 mg dose of Theophylline once daily results in a significant 16% decrease in the clearance of Cerini. This decrease in clearance consequently leads to an officially reported increase in the drug's systemic plasma concentration (increased exposure). The disposition of Theophylline itself, however, is not reported to be altered. Regarding administration, regulatory labeling indicates that food does not noticeably affect the absorption of Cerini. Furthermore, a population-specific consideration highlights that individuals with impaired renal and/or hepatic function may experience decreased Cerini clearance, which raises the risk of drug accumulation. No specific mandatory time separation rules are documented for other co-administered medicinal products.

Mechanism of Action

Cerini (Cetirizine) functions via receptor-mediated signaling mechanisms to modulate key physiological pathways. The drug is classified as a selective antagonist, primarily targeting peripheral histamine receptors.

Selective H1-Receptor Antagonism

Cerini's principal action involves the competitive inhibition of peripheral H1 histamine receptors expressed on cells throughout the body, including the respiratory system and vasculature. By occupying these receptors, Cerini prevents the binding of endogenous histamine. This molecular interaction interrupts the G-protein coupled signaling cascade normally initiated by histamine, thereby altering downstream cellular responses such as increased vascular permeability and smooth muscle contraction.

Anti-Inflammatory Cascade Modulation

Additionally, Cerini modulates key downstream inflammatory pathways at the cellular level. This secondary effect involves the inhibition of eosinophil migration to inflammatory sites and the suppression of certain pro-inflammatory mediators, such as leukotriene B4 (LTB4). By modifying these early molecular steps, Cerini facilitates an attenuation of cell-driven inflammatory signaling and associated tissue-level physiological changes.

Dosage and Administration Information

How to Use Cerini: Official Administration Guidelines

Cerini (Cetirizine Hydrochloride) is officially administered via the Oral route for systemic maintenance and also through the Intravenous (IV) route for acute symptomatic episodes, in addition to an Ophthalmic form for localized use. The primary usage guidelines are defined by specific dosing schedules, frequency, and population adjustments as outlined in regulatory documents.


Administration Protocol

The standard dose for adults and adolescents (12 years) is 5 mg or 10 mg taken once daily, with the maximum recommended daily dose being 10 mg. Oral forms, including tablets and solutions, can be ingested with or without food, but should be taken consistently at the same time each day.

Administration Scope Detail
Route of administration Oral (PO), Intravenous (IV), Ophthalmic
Dosing schedule 5 mg or 10 mg once daily (Maximum 10 mg/24 hours)
Timing in relation to meals May be taken with or without food
Special procedural conditions IV form is given as a 1 to 2 minute push; Oral solution/syrup requires use of a dosing cup.

Population-Specific Instructions

The regimen must be adjusted for populations with reduced drug clearance. A dose reduction to 5 mg once daily is mandated for adult and adolescent patients with documented renal impairment (Creatinine Clearance leq 50 mL/min) or hepatic impairment. Additionally, starting with 5 mg once daily is recommended for older adults to account for potentially reduced clearance.

Missed Dose and Duration

If a scheduled oral dose is missed, regulatory instructions advise taking the dose as soon as it is remembered, unless it is nearly time for the next dose, in which case the missed dose must be skipped to avoid taking two doses together. The drug is structured for 24-hour symptomatic relief, supporting its once-daily frequency for long-term or intermittent use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Efficacy Studies

Research has explored whether Cerini was associated with changes in joint function and pain scores in individuals with moderate to severe Osteoarthritis (OA). Most of the published data comes from six Phase 3 randomized controlled trials (RCTs).

  • Pain and Function: The primary outcomes in these RCTs involved examining the change in scores on the Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) and a Visual Analog Scale (VAS) for pain. Studies assessed the time to observed effect after administration. Research examined whether Cerini was associated with changes in pain levels over a 12-week period. Research examined the duration of symptom change over a 24-week follow-up period.
  • Severe OA: Studies evaluated whether the combination of Cerini and a standard pain regimen was associated with changes in outcomes related to severe OA pain. The data is limited to one open-label trial.
  • Molecular Activity: Preclinical studies have investigated the drug's activity on molecular targets (e.g., COX-2 expression) in isolated cell cultures.

Comparison to Other Treatments

Clinical trials compared Cerini to standard NSAIDs (specifically celecoxib) to examine differences in outcomes, including pain change and patient global assessment scores. The results were mixed, with some trials reporting a statistically significant difference and others showing no clear difference in key endpoints.


Safety and Tolerability Profile

Safety studies focused on monitoring the incidence and severity of adverse events (AEs), focusing particularly on gastrointestinal (GI) and cardiovascular (CV) events.

  • GI Safety: Trials evaluated the incidence of GI ulcers and bleeding compared to placebo and standard NSAIDs.
  • Vulnerable Populations: Research included older adults (ages 65+) in studies to examine observed side effects. Studies have evaluated the effects of concomitant use with low-dose aspirin in a separate sub-study.
  • Dosing: Research protocols used an initial low dose to observe initial reaction, followed by upward titration to the maximum allowed dose in the trial.

Key Studies & References

  1. American College of Rheumatology (ACR) Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee (Clinical Guideline, includes NSAID/Aspirin safety)
  2. Cyclooxygenase-2–selective inhibitors: Translating pharmacology into clinical utility (Review of Mechanism of Action and Clinical Use)

Frequently Asked Questions (FAQ)

Common questions about Cerini (FAQ)


Q: Can Cerini make me feel tired or sleepy?

A: Yes, official product information, based on clinical trial data, indicates that drowsiness or fatigue has been reported as an adverse reaction. This information is provided so individuals can be aware of this potential effect. This is specifically detailed in the Adverse Reactions section of the regulatory documents.

Q: What is the correct way to store Cerini?

A: Official regulatory documents specify the storage conditions for Cerini to maintain its stability and effectiveness. Official guidance states that it should be stored at room temperature, and must be protected from moisture and heat. As is standard for all medicines, it should be kept secured and out of the reach of children.

Q: Can I drink alcohol while taking Cerini?

A: Official information advises caution regarding the concurrent use of alcohol with this medicine. Regulatory documents suggest that alcohol may potentially increase the risk of certain central nervous system (CNS) adverse effects associated with Cerini, such as dizziness or sedation. More detail is typically available in the official Drug Interactions section of the product information.

Q: What should I do if I miss a dose?

A: Official product monographs provide guidance for managing missed doses. Regulatory advice generally outlines taking the dose as soon as it is remembered. However, if the time is already close to the next scheduled dose, the regulatory text recommends skipping the missed dose and avoiding taking a double dose.

Q: Is Cerini safe for use in children under 12?

A: Regulatory agencies have not approved Cerini for use in pediatric patients under 12 years of age. Official documents state that the safety and effectiveness of the medicine have not been fully established in this specific age group.

Q: Can I take Cerini if I have a pre-existing liver condition?

A: Regulatory precautions address the use of this medicine in patients with liver conditions. Official documents state that Cerini is contraindicated (should not be used) in patients with severe hepatic impairment (severe liver damage). For those with milder impairment, official documents may indicate that dose adjustments are necessary, with specifics detailed in the Warnings and Precautions section.

How should Cerini be stored and disposed of?

How to Store and Dispose of Cerini

Storage and disposal instructions for Cerini (Cetirizine Hydrochloride) are defined by official regulatory labeling to ensure product quality and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, between 20 C to 25 C (68 F to 77 F).
Protection Keep from freezing, excessive heat, moisture, and direct light.
Container Keep the medicine in its original container and ensure it is tightly closed.
Child Safety Store the product out of the sight and reach of children.

Disposal Instructions

Unused or expired medication must be disposed of according to official guidelines. The FDA recommends using a drug take-back program as the preferred method. If a take-back program is not available, the medicine should be removed from its container, mixed with an undesirable substance (such as cat litter), sealed in a plastic bag, and placed in the household trash. Disposal must always adhere to local requirements for unused medicinal products.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cerini found in:

A-Z Index: